Concerns about Delta variant have made many laboratories that already have their vaccines approved against COVID-19, have decided to start studies to tailor efficacy against this contagious strain. One such company is Pfizer, which this July 8 announced that it is already in the process of updating.
“Pfizer and BioNTech are conducting tests to confirm this expectation,” according to a press release issued late Thursday.
Both labs, which have worked together on the vaccine called BNT162b2, will make this update to directly address the Delta variant. For now they are producing material for a clinical trial, which they expect to begin in August, pending regulatory approvals from the FDA.
But that is not all, since Pfizer and BioNTech are looking closely at the situation in Israel, where the Delta variant increased infections again, despite the high vaccination rate.
This has triggered that they are already thinking of a third booster dose for the month of August, when in countries like the United States for example, more than six months have already been completed for the first people with both doses.
“As seen in the real world evidence published by the Israeli Ministry of Health, the efficacy of the vaccine has decreased six months after vaccination, at the same time that the Delta variant is becoming the dominant variant in the country. . These findings are consistent with an ongoing analysis of the Phase 3 study of the companies. That is why we have said, and continue to believe that it is likely, based on the totality of the data we have to date, that a third dose will be needed within 6 to 12 months after full vaccination, “they concluded.